[
  {
    "ts": null,
    "headline": "RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit",
    "summary": "Health Secretary Robert F. Kennedy Jr. named eight new members to the CDC’s Advisory Committee on Immunization Practices on Wednesday, including several anti-vaccine proponents, after dismissing all 17 existing advisers. Kennedy justified the overhaul to “re-establish public confidence in vaccine science,” claiming, without providing specific evidence, that prior Biden-appointed members had conflicts of interest. The new eight-member committee represents the minimum allowed under ACIP’s founding",
    "url": "https://finnhub.io/api/news?id=7e28ebed6ebb0b232be2a9e444d89f7361a0081c847e471204653ed0642d12ec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749857498,
      "headline": "RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit",
      "id": 135261011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Health Secretary Robert F. Kennedy Jr. named eight new members to the CDC’s Advisory Committee on Immunization Practices on Wednesday, including several anti-vaccine proponents, after dismissing all 17 existing advisers. Kennedy justified the overhaul to “re-establish public confidence in vaccine science,” claiming, without providing specific evidence, that prior Biden-appointed members had conflicts of interest. The new eight-member committee represents the minimum allowed under ACIP’s founding",
      "url": "https://finnhub.io/api/news?id=7e28ebed6ebb0b232be2a9e444d89f7361a0081c847e471204653ed0642d12ec"
    }
  },
  {
    "ts": null,
    "headline": "Citizens Financial, Merck, oil producers: Trending Tickers",
    "summary": "Citizens Financial Group (CFG) will be expanding its share buyback program to $1.5 billion. Pharmaceutical giant Merck (MRK) received approval from the US Food and Drug Administration (FDA) to use Keytruda to treat head and neck cancer. Shares of American oil producers, namely Occidental Petroleum (OXY), climb higher in response to spiking oil prices (CL=F, BZ=F) after Israel coordinated airstrikes against Iran. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.",
    "url": "https://finnhub.io/api/news?id=1aa3d86b1dfba34c16e673123b89592565b0b54f25e1ec7df18f7ecfcc9fd9a1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749826809,
      "headline": "Citizens Financial, Merck, oil producers: Trending Tickers",
      "id": 135249528,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Citizens Financial Group (CFG) will be expanding its share buyback program to $1.5 billion. Pharmaceutical giant Merck (MRK) received approval from the US Food and Drug Administration (FDA) to use Keytruda to treat head and neck cancer. Shares of American oil producers, namely Occidental Petroleum (OXY), climb higher in response to spiking oil prices (CL=F, BZ=F) after Israel coordinated airstrikes against Iran. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.",
      "url": "https://finnhub.io/api/news?id=1aa3d86b1dfba34c16e673123b89592565b0b54f25e1ec7df18f7ecfcc9fd9a1"
    }
  },
  {
    "ts": null,
    "headline": "Investors should be 'embracing volatility'",
    "summary": "Market volatility can be scary for investors, but it can also bring opportunity. In the video above, Kovitz Investment Group portfolio manager John Buckingham explains why investors should be \"embracing volatility.\" He also shares five stocks he's interested in now.  To watch more expert insights and analysis on the latest market action, check out more Wealth here.",
    "url": "https://finnhub.io/api/news?id=0ca918d098bdac8808763068d38203c3e13517472a0b3645cf4fd663c42b0764",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749812413,
      "headline": "Investors should be 'embracing volatility'",
      "id": 135242745,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Market volatility can be scary for investors, but it can also bring opportunity. In the video above, Kovitz Investment Group portfolio manager John Buckingham explains why investors should be \"embracing volatility.\" He also shares five stocks he's interested in now.  To watch more expert insights and analysis on the latest market action, check out more Wealth here.",
      "url": "https://finnhub.io/api/news?id=0ca918d098bdac8808763068d38203c3e13517472a0b3645cf4fd663c42b0764"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent",
    "summary": "RAHWAY, N.J., June 13, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, contin",
    "url": "https://finnhub.io/api/news?id=d84bdd12881209b3ca28c48b143ed9769cc2e367946dc9c724c001a844d9b5d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749811500,
      "headline": "FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent",
      "id": 135248687,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., June 13, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, contin",
      "url": "https://finnhub.io/api/news?id=d84bdd12881209b3ca28c48b143ed9769cc2e367946dc9c724c001a844d9b5d4"
    }
  },
  {
    "ts": null,
    "headline": "MSD begins Phase III trial of dengue vaccine",
    "summary": "The trial aims to enrol approximately 12,000 healthy individuals aged two to 17 years old.",
    "url": "https://finnhub.io/api/news?id=863c10dcb63a82132c23f89533b388223c45d3a4c026dbfdf096be61eede5362",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749807118,
      "headline": "MSD begins Phase III trial of dengue vaccine",
      "id": 135248690,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The trial aims to enrol approximately 12,000 healthy individuals aged two to 17 years old.",
      "url": "https://finnhub.io/api/news?id=863c10dcb63a82132c23f89533b388223c45d3a4c026dbfdf096be61eede5362"
    }
  },
  {
    "ts": null,
    "headline": "Merck: FDA approves Keytruda for head and neck cancer",
    "summary": "Merck announces that the US FDA has approved Keytruda for the treatment of adult patients with locally advanced head and neck squamous cell carcinoma that is resectable and PD-L1-expressing. This...",
    "url": "https://finnhub.io/api/news?id=ddaf8d7d117c248f4e5bbb01b49104a6e03c56f8e7726b08512ddc8d7b4cbf21",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749802238,
      "headline": "Merck: FDA approves Keytruda for head and neck cancer",
      "id": 135237354,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announces that the US FDA has approved Keytruda for the treatment of adult patients with locally advanced head and neck squamous cell carcinoma that is resectable and PD-L1-expressing. This...",
      "url": "https://finnhub.io/api/news?id=ddaf8d7d117c248f4e5bbb01b49104a6e03c56f8e7726b08512ddc8d7b4cbf21"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Merck's Anti-PD-1 Therapy",
    "summary": "Merck announced that the U.S. Food and Drug Administration has approved KEYTRUDA®? , Merck's anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck...",
    "url": "https://finnhub.io/api/news?id=d2e68512e57a1ec102ffd4159b91e3555dc5ae313be373565f5665caa0d80c7c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749801038,
      "headline": "FDA Approves Merck's Anti-PD-1 Therapy",
      "id": 135237209,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announced that the U.S. Food and Drug Administration has approved KEYTRUDA®? , Merck's anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck...",
      "url": "https://finnhub.io/api/news?id=d2e68512e57a1ec102ffd4159b91e3555dc5ae313be373565f5665caa0d80c7c"
    }
  },
  {
    "ts": null,
    "headline": "Merck Receives FDA Approval for Treatment of Head, Neck Cancers",
    "summary": "By Connor Hart The Food and Drug Administration approved Merck's treatment for certain head and neck cancers. The Rahway, N.J., drug maker said Friday that its treatment, Keytruda, has been...",
    "url": "https://finnhub.io/api/news?id=6a5e870502c72851168024f19d156b90297f15633eebf70d465be721acf22df1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749799996,
      "headline": "Merck Receives FDA Approval for Treatment of Head, Neck Cancers",
      "id": 135237114,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "By Connor Hart The Food and Drug Administration approved Merck's treatment for certain head and neck cancers. The Rahway, N.J., drug maker said Friday that its treatment, Keytruda, has been...",
      "url": "https://finnhub.io/api/news?id=6a5e870502c72851168024f19d156b90297f15633eebf70d465be721acf22df1"
    }
  }
]